Share Price and Basic Stock Data
Last Updated: October 15, 2025, 3:13 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Mangalam Drugs and Organics Ltd operates in the pharmaceuticals sector, with its latest share price reported at ₹69.3 and a market capitalization of ₹109 Cr. The company recorded sales of ₹372 Cr for the fiscal year ending March 2023, a decline from ₹451 Cr in the previous year. Quarterly sales figures show fluctuations, with a high of ₹109 Cr in June 2022 and a low of ₹57 Cr in June 2025. The sales trajectory indicates a notable decrease over the past few quarters, particularly in the trailing twelve months, where sales stood at ₹318 Cr for FY 2025. This decline could be attributed to various market pressures, including competition and operational inefficiencies, impacting revenue generation. The operating profit margin (OPM) has also seen instability, particularly reflecting a negative margin of -8% as of the latest quarter, indicating challenges in controlling operational costs. The company’s revenue performance requires close monitoring to assess recovery strategies and potential growth areas in the competitive pharmaceutical landscape.
Profitability and Efficiency Metrics
The profitability of Mangalam Drugs and Organics Ltd has been under pressure, with a reported net profit of ₹7 Cr for FY 2023, down from ₹20 Cr in FY 2022. The operating profit margin shows a concerning trend, starting at 9% in June 2022 and declining to -8% by June 2025. The company’s interest coverage ratio stands at 1.26x, suggesting limited ability to cover interest expenses with operating income, which can pose risks in a rising interest rate environment. Return on equity (ROE) is reported at 4.71%, while return on capital employed (ROCE) is at 8.03%, reflecting a modest return relative to industry standards. The cash conversion cycle of 148 days indicates inefficiencies in managing working capital, particularly with inventory days extending to 303, suggesting excess stockholding or slow turnover. The company must enhance its operational efficiency and profitability metrics to regain investor confidence and improve overall financial health.
Balance Sheet Strength and Financial Ratios
Mangalam Drugs and Organics Ltd’s balance sheet reflects a total borrowing of ₹96 Cr against reserves of ₹133 Cr, indicating a manageable debt-to-equity ratio of approximately 0.64x. This level of leverage suggests that while the company has a reasonable cushion of reserves, it still relies significantly on debt to finance its operations. The current ratio is reported at 1.07, which is slightly above the benchmark of 1, indicating adequate short-term liquidity. However, the quick ratio of 0.31 points to potential liquidity challenges, as it excludes inventory from current assets. The book value per share stands at ₹85.79, which, when compared to the current price, shows a price-to-book ratio of 1.08x, suggesting that shares are trading at a slight premium to their book value. Overall, while the balance sheet shows some stability, the company must focus on improving liquidity and managing debt levels effectively moving forward.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Mangalam Drugs and Organics Ltd indicates a stable ownership structure, with promoters holding 50.30% of the shares, suggesting strong insider confidence in the company. Foreign institutional investors (FIIs) hold a modest 0.53%, while public ownership accounts for 49.16%. The number of shareholders has increased to 19,728 as of June 2025, reflecting growing interest in the stock. However, the low FII participation may indicate a lack of broader market confidence. The stability in promoter shareholding, which has remained consistent over recent quarters, is a positive sign, as it suggests alignment of interests between management and shareholders. For investor confidence to strengthen further, the company must demonstrate improved financial performance and address operational inefficiencies that have impacted profitability.
Outlook, Risks, and Final Insight
If Mangalam Drugs and Organics Ltd can implement effective strategies to enhance its operational efficiency and profitability, it may stabilize its revenue and improve financial metrics. Addressing the high cash conversion cycle and managing inventory levels will be crucial in this regard. However, the company faces risks, including fluctuating sales figures and a challenging interest coverage ratio, which could strain financial performance if not managed effectively. Additionally, the competitive landscape of the pharmaceutical industry poses ongoing challenges that the company must navigate. Strengthening its balance sheet and improving liquidity will be vital for sustaining growth. Overall, while the company has a solid foundation, tangible improvements in efficiency and profitability will be necessary to foster investor confidence and drive future success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Mangalam Drugs and Organics Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 149 Cr. | 118 | 247/84.3 | 33.8 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,488 Cr. | 412 | 434/192 | 101 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 40.4 Cr. | 54.5 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 30.7 Cr. | 20.9 | 29.1/17.0 | 32.0 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 18,851.99 Cr | 1,169.54 | 49.75 | 192.71 | 0.34% | 16.15% | 14.90% | 6.18 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 109 | 108 | 63 | 91 | 87 | 82 | 97 | 102 | 77 | 80 | 89 | 73 | 57 |
| Expenses | 99 | 100 | 57 | 91 | 91 | 79 | 90 | 91 | 68 | 71 | 80 | 63 | 62 |
| Operating Profit | 10 | 8 | 6 | 0 | -3 | 2 | 7 | 12 | 8 | 9 | 9 | 10 | -5 |
| OPM % | 9% | 8% | 10% | 0% | -4% | 3% | 7% | 11% | 11% | 11% | 10% | 14% | -8% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 3 | 4 | 4 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 |
| Profit before tax | 4 | 3 | 1 | -6 | -10 | -5 | 0 | 4 | 1 | 1 | 1 | 2 | -13 |
| Tax % | 29% | 29% | 16% | -22% | -7% | -25% | -920% | 10% | -356% | -125% | 5% | 91% | 6% |
| Net Profit | 3 | 2 | 0 | -4 | -10 | -4 | 0 | 4 | 3 | 3 | 1 | 0 | -14 |
| EPS in Rs | 1.90 | 1.41 | 0.27 | -2.77 | -6.03 | -2.25 | 0.32 | 2.24 | 1.69 | 1.70 | 0.88 | 0.09 | -8.67 |
Last Updated: August 20, 2025, 7:15 am
Below is a detailed analysis of the quarterly data for Mangalam Drugs and Organics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 57.00 Cr.. The value appears to be declining and may need further review. It has decreased from 73.00 Cr. (Mar 2025) to 57.00 Cr., marking a decrease of 16.00 Cr..
- For Expenses, as of Jun 2025, the value is 62.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 63.00 Cr. (Mar 2025) to 62.00 Cr., marking a decrease of 1.00 Cr..
- For Operating Profit, as of Jun 2025, the value is -5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 10.00 Cr. (Mar 2025) to -5.00 Cr., marking a decrease of 15.00 Cr..
- For OPM %, as of Jun 2025, the value is -8.00%. The value appears to be declining and may need further review. It has decreased from 14.00% (Mar 2025) to -8.00%, marking a decrease of 22.00%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.00 Cr..
- For Depreciation, as of Jun 2025, the value is 4.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2025) to -13.00 Cr., marking a decrease of 15.00 Cr..
- For Tax %, as of Jun 2025, the value is 6.00%. The value appears to be improving (decreasing) as expected. It has decreased from 91.00% (Mar 2025) to 6.00%, marking a decrease of 85.00%.
- For Net Profit, as of Jun 2025, the value is -14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.00 Cr. (Mar 2025) to -14.00 Cr., marking a decrease of 14.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -8.67. The value appears to be declining and may need further review. It has decreased from 0.09 (Mar 2025) to -8.67, marking a decrease of 8.76.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:53 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 123 | 221 | 295 | 299 | 269 | 228 | 282 | 380 | 451 | 372 | 369 | 318 | 299 |
| Expenses | 113 | 200 | 257 | 252 | 222 | 218 | 259 | 327 | 402 | 347 | 351 | 282 | 276 |
| Operating Profit | 10 | 20 | 38 | 47 | 47 | 10 | 24 | 53 | 49 | 26 | 17 | 36 | 23 |
| OPM % | 8% | 9% | 13% | 16% | 17% | 4% | 8% | 14% | 11% | 7% | 5% | 11% | 8% |
| Other Income | 0 | 0 | 0 | -0 | 1 | 0 | 1 | 5 | 0 | 0 | 0 | 0 | 0 |
| Interest | 10 | 10 | 9 | 10 | 12 | 9 | 10 | 9 | 11 | 13 | 14 | 15 | 15 |
| Depreciation | 4 | 4 | 4 | 5 | 7 | 7 | 8 | 9 | 10 | 11 | 15 | 16 | 17 |
| Profit before tax | -4 | 6 | 24 | 31 | 29 | -6 | 6 | 40 | 28 | 2 | -11 | 5 | -9 |
| Tax % | -22% | -2% | 33% | 29% | 32% | 40% | -32% | 29% | 29% | 43% | -18% | -39% | |
| Net Profit | -3 | 6 | 16 | 22 | 20 | -8 | 8 | 28 | 20 | 1 | -9 | 7 | -9 |
| EPS in Rs | -2.31 | 4.66 | 11.15 | 14.08 | 12.57 | -5.07 | 5.21 | 17.67 | 12.42 | 0.80 | -5.72 | 4.37 | -6.00 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 300.00% | 166.67% | 37.50% | -9.09% | -140.00% | 200.00% | 250.00% | -28.57% | -95.00% | -1000.00% | 177.78% |
| Change in YoY Net Profit Growth (%) | 0.00% | -133.33% | -129.17% | -46.59% | -130.91% | 340.00% | 50.00% | -278.57% | -66.43% | -905.00% | 1177.78% |
Mangalam Drugs and Organics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: October 10, 2025, 2:30 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 14 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 10 | 16 | 47 | 70 | 88 | 80 | 88 | 115 | 135 | 136 | 127 | 133 |
| Borrowings | 77 | 78 | 60 | 66 | 69 | 65 | 52 | 70 | 88 | 89 | 107 | 96 |
| Other Liabilities | 25 | 63 | 38 | 38 | 54 | 50 | 75 | 64 | 90 | 117 | 108 | 114 |
| Total Liabilities | 125 | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 357 | 359 |
| Fixed Assets | 53 | 53 | 54 | 93 | 102 | 103 | 101 | 118 | 135 | 142 | 147 | 156 |
| CWIP | 0 | 0 | 5 | 0 | 0 | 0 | 1 | 6 | 6 | 9 | 8 | 3 |
| Investments | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 72 | 117 | 100 | 95 | 125 | 107 | 128 | 140 | 188 | 206 | 202 | 201 |
| Total Assets | 125 | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 357 | 359 |
Below is a detailed analysis of the balance sheet data for Mangalam Drugs and Organics Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 16.00 Cr..
- For Reserves, as of Mar 2025, the value is 133.00 Cr.. The value appears strong and on an upward trend. It has increased from 127.00 Cr. (Mar 2024) to 133.00 Cr., marking an increase of 6.00 Cr..
- For Borrowings, as of Mar 2025, the value is 96.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 107.00 Cr. (Mar 2024) to 96.00 Cr., marking a decrease of 11.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 114.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 108.00 Cr. (Mar 2024) to 114.00 Cr., marking an increase of 6.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 359.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 357.00 Cr. (Mar 2024) to 359.00 Cr., marking an increase of 2.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 156.00 Cr.. The value appears strong and on an upward trend. It has increased from 147.00 Cr. (Mar 2024) to 156.00 Cr., marking an increase of 9.00 Cr..
- For CWIP, as of Mar 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Mar 2024) to 3.00 Cr., marking a decrease of 5.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 201.00 Cr.. The value appears to be declining and may need further review. It has decreased from 202.00 Cr. (Mar 2024) to 201.00 Cr., marking a decrease of 1.00 Cr..
- For Total Assets, as of Mar 2025, the value is 359.00 Cr.. The value appears strong and on an upward trend. It has increased from 357.00 Cr. (Mar 2024) to 359.00 Cr., marking an increase of 2.00 Cr..
Notably, the Reserves (133.00 Cr.) exceed the Borrowings (96.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -67.00 | -58.00 | -22.00 | -19.00 | -22.00 | -55.00 | -28.00 | -17.00 | -39.00 | -63.00 | -90.00 | -60.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88 | 73 | 37 | 45 | 61 | 28 | 52 | 52 | 38 | 46 | 28 | 45 |
| Inventory Days | 170 | 134 | 85 | 69 | 132 | 175 | 121 | 85 | 139 | 200 | 185 | 303 |
| Days Payable | 97 | 128 | 37 | 38 | 82 | 77 | 106 | 63 | 65 | 139 | 124 | 199 |
| Cash Conversion Cycle | 161 | 79 | 85 | 75 | 111 | 126 | 67 | 74 | 112 | 107 | 88 | 148 |
| Working Capital Days | 29 | 26 | 32 | 19 | 31 | 21 | 10 | 23 | 43 | 38 | 18 | 13 |
| ROCE % | 6% | 16% | 29% | 31% | 25% | 2% | 11% | 27% | 18% | 6% | 1% | 8% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 24 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | -5.73 |
| Diluted EPS (Rs.) | -5.73 |
| Cash EPS (Rs.) | 3.52 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 85.79 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 85.79 |
| Revenue From Operations / Share (Rs.) | 232.87 |
| PBDIT / Share (Rs.) | 11.05 |
| PBIT / Share (Rs.) | 1.80 |
| PBT / Share (Rs.) | -7.00 |
| Net Profit / Share (Rs.) | -5.73 |
| NP After MI And SOA / Share (Rs.) | -5.73 |
| PBDIT Margin (%) | 4.74 |
| PBIT Margin (%) | 0.77 |
| PBT Margin (%) | -3.00 |
| Net Profit Margin (%) | -2.46 |
| NP After MI And SOA Margin (%) | -2.46 |
| Return on Networth / Equity (%) | -6.68 |
| Return on Capital Employeed (%) | 1.67 |
| Return On Assets (%) | -2.71 |
| Long Term Debt / Equity (X) | 0.09 |
| Total Debt / Equity (X) | 0.64 |
| Current Ratio (X) | 1.07 |
| Quick Ratio (X) | 0.31 |
| Interest Coverage Ratio (X) | 1.26 |
| Interest Coverage Ratio (Post Tax) (X) | 0.34 |
| Enterprise Value (Cr.) | 233.41 |
| EV / Net Operating Revenue (X) | 0.63 |
| EV / EBITDA (X) | 13.34 |
| MarketCap / Net Operating Revenue (X) | 0.39 |
| Price / BV (X) | 1.08 |
| Price / Net Operating Revenue (X) | 0.39 |
| EarningsYield | -0.06 |
After reviewing the key financial ratios for Mangalam Drugs and Organics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 24, the value is -5.73. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 24, the value is -5.73. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 24, the value is 3.52. This value is within the healthy range. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 85.79. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 85.79. No previous period data is available for comparison.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 232.87. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 11.05. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 24, the value is 1.80. This value is within the healthy range. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 24, the value is -7.00. This value is below the healthy minimum of 0. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 24, the value is -5.73. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is -5.73. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For PBDIT Margin (%), as of Mar 24, the value is 4.74. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For PBIT Margin (%), as of Mar 24, the value is 0.77. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For PBT Margin (%), as of Mar 24, the value is -3.00. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Net Profit Margin (%), as of Mar 24, the value is -2.46. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is -2.46. This value is below the healthy minimum of 8. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 24, the value is -6.68. This value is below the healthy minimum of 15. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 24, the value is 1.67. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 24, the value is -2.71. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.09. This value is below the healthy minimum of 0.2. No previous period data is available for comparison.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.64. This value is within the healthy range. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 24, the value is 1.07. This value is below the healthy minimum of 1.5. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 24, the value is 0.31. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 1.26. This value is below the healthy minimum of 3. No previous period data is available for comparison.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 0.34. This value is below the healthy minimum of 3. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 24, the value is 233.41. No previous period data is available for comparison.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 0.63. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 24, the value is 13.34. This value is within the healthy range. No previous period data is available for comparison.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 0.39. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 24, the value is 1.08. This value is within the healthy range. No previous period data is available for comparison.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 0.39. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For EarningsYield, as of Mar 24, the value is -0.06. This value is below the healthy minimum of 5. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Mangalam Drugs and Organics Ltd:
- Net Profit Margin: -2.46%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 1.67% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -6.68% (Industry Average ROE: 14.9%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.34
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.31
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 49.75)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.64
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -2.46%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Rupam Building, 3rd Floor, 239, P.D. Mello Road, Mumbai Maharashtra 400001 | contactus@mangalamdrugs.com http://www.mangalamdrugs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Govardhan Murlidhar Dhoot | Chairman & Managing Director |
| Mr. Brijmohan Murlidhar Dhoot | Whole Time Director |
| Mr. Rakesh Kishinchand Milwani | Non Exe.Non Ind.Director |
| Mr. Rukmesh Prabhukumar Dhandhania | Independent Director |
| Mrs. Nidhi Shantanu Mundada | Independent Director |
| Mr. Praveen Saxena | Independent Director |
FAQ
What is the intrinsic value of Mangalam Drugs and Organics Ltd?
Mangalam Drugs and Organics Ltd's intrinsic value (as of 14 October 2025) is 54.13 which is 22.78% lower the current market price of 70.10, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹111 Cr. market cap, FY2025-2026 high/low of 130/65.5, reserves of ₹133 Cr, and liabilities of 359 Cr.
What is the Market Cap of Mangalam Drugs and Organics Ltd?
The Market Cap of Mangalam Drugs and Organics Ltd is 111 Cr..
What is the current Stock Price of Mangalam Drugs and Organics Ltd as on 14 October 2025?
The current stock price of Mangalam Drugs and Organics Ltd as on 14 October 2025 is 70.1.
What is the High / Low of Mangalam Drugs and Organics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Mangalam Drugs and Organics Ltd stocks is 130/65.5.
What is the Stock P/E of Mangalam Drugs and Organics Ltd?
The Stock P/E of Mangalam Drugs and Organics Ltd is .
What is the Book Value of Mangalam Drugs and Organics Ltd?
The Book Value of Mangalam Drugs and Organics Ltd is 93.9.
What is the Dividend Yield of Mangalam Drugs and Organics Ltd?
The Dividend Yield of Mangalam Drugs and Organics Ltd is 0.00 %.
What is the ROCE of Mangalam Drugs and Organics Ltd?
The ROCE of Mangalam Drugs and Organics Ltd is 8.03 %.
What is the ROE of Mangalam Drugs and Organics Ltd?
The ROE of Mangalam Drugs and Organics Ltd is 4.71 %.
What is the Face Value of Mangalam Drugs and Organics Ltd?
The Face Value of Mangalam Drugs and Organics Ltd is 10.0.